
How Pharma Should Prep for the Six-bill Avalanche From Congress
The bipartisan legislative push could create big hurdles for drug development, with concerns mounting over limited patent protections and increased litigation risks, hears Marisa Woutersen. The US pharmaceutical industry may soon face major regulatory …